Navigation Links
Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Date:6/26/2012

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

The study randomized 74 patients, ages 16 to 70, to receive either SIR/TAC or MTX/TAC. Patients were stratified by donor relation (siblings or matched, unrelated individuals) and age.

Their study was published in a recent issue of Haematologica, the journal of the European Hematology Association.

"Graft vs. host disease poses major health problems for patients who have received hematopoietic cell transplants and threatens the long-term success of their transplant," said Joseph Pidala, M.D., M.S., a medical oncologist and study principal investigator. "Existing pharmacologic strategies do not adequately prevent acute graft vs. host disease following allogeneic hematopoietic (blood) cell transplantation, and effective acute GVHD prevention is an important clinical goal necessary to ensure the long-term success of transplantation."

According to the authors, their study design mandated at least one year of sirolimus therapy in order to both limit the risk from chronic GVHD development and to promote the patients' immune tolerance based on the "reconstitution" of the patients' immune cells, called regulatory T cells, or "Tregs."

"Our hypothesis was that SIR-based immune suppression would suppress alloreactive T cells, support the recovery of the immune system's Tregs, and more effectively prevent GVHD," explained Pidala.

Results showed that on days 30 and 90 post transplantation, SIR/TAC-treated patients had "a significantly greater proportion of regulatory T cells among the CD 4 immune cells in their peripheral blood" and their regulatory Tregs were "functional."

The authors suggested that the "net benefit" observed in Treg reconstitution with SIR/TAC-treated patients was likely due to both the suppression of immune systems' non-Treg CD4 T cells by sirolimus, as well as the lower tacrolimus exposure for these patients as compared to patients on the MTX/TAC arm of the study.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
2. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
3. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
4. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
5. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
6. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Moffitt researcher publishes book on nutritional management of cancer treatment effects
10. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
11. Moffitt Cancer Center researchers working at frontiers of melanoma research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... Gout ... switch, and brings pain that is often severe, with intense swelling and redness. It ... than eight million people, but older adults are the most susceptible, according to the ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
(Date:2/10/2016)... ... 2016 , ... A national ergonomics pioneer , HealthPostures, ... March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the expo will ... running and largest worker's compensation event in Ohio, organizers of the safety congress ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 ... window and M 1 receptor selectivity   ... Heptares StaR® technology, which has entered clinical development ... patients with dementia and schizophrenia.   --> ... StaR® technology, which has entered clinical development as ...
(Date:2/9/2016)... FARMINGDALE, N.Y., Feb. 9, 2016  Misonix, Inc. ... company that designs, manufactures and markets innovative therapeutic ... wound debridement, cosmetic surgery, laparoscopic surgery and other ... second quarter and the first half of fiscal ... --> --> Highlights ...
(Date:2/9/2016)... Mass. , Feb. 9, 2016  Insulet Corporation (NASDAQ: ... tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s Board ... of nine directors, eight of whom are independent. ... 40 years of audit and finance experience and a deep ...
Breaking Medicine Technology: